Abstract | AIM: METHODS: The study was performed prospectively in 7 patients with arteriosclerosis obliterans. Beraprost sodium (40 microg) was orally administered to 7 patients at study entry, followed by administration of 120 microg/day for 12 weeks. Blood sampling and measurements of flow-mediated vasodilatation were performed before and after treatment at study entry, 4 weeks, and 12 weeks after treatment. Treadmill exercise tests were performed three times at study entry, 4 weeks, and 12 weeks after treatment. The ankle-brachial index (ABI) was measured at rest and after exercise. RESULTS: CONCLUSION:
|
Authors | T Matsumoto, K Iwasa, R Kyuragi, K Honma, A Guntani, T Ohmine, H Itoh, T Onohara, Y Maehara |
Journal | International angiology : a journal of the International Union of Angiology
(Int Angiol)
Vol. 29
Issue 2 Suppl
Pg. 49-54
(Apr 2010)
ISSN: 1827-1839 [Electronic] Italy |
PMID | 20357749
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Biomarkers
- Endothelin-1
- Platelet Aggregation Inhibitors
- Vasodilator Agents
- beraprost
- symmetric dimethylarginine
- Arginine
- Epoprostenol
|
Topics |
- Administration, Oral
- Aged
- Ankle Brachial Index
- Arginine
(analogs & derivatives, blood)
- Arteriosclerosis Obliterans
(blood, complications, drug therapy, physiopathology)
- Biomarkers
(blood)
- Endothelin-1
(blood)
- Epoprostenol
(administration & dosage, analogs & derivatives)
- Exercise Test
- Exercise Tolerance
(drug effects)
- Humans
- Intermittent Claudication
(blood, drug therapy, etiology, physiopathology)
- Platelet Aggregation Inhibitors
(administration & dosage)
- Prospective Studies
- Time Factors
- Treatment Outcome
- Vasodilation
(drug effects)
- Vasodilator Agents
(administration & dosage)
- Walking
|